In This Article:
Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer therapy pipeline.
The collaboration builds upon previous joint efforts, utilising AI and data to propel research and the development of therapeutics.
Despite advances in understanding, preventing and treating cancer, the disease continues to pose a substantial challenge, burdening healthcare systems.
Boehringer is focused on altering this landscape by fostering the discovery and development of treatments for individuals with difficult-to-treat cancers.
Boehringer will gain access to the de-identified database of Tempus, which includes clinical, imaging and molecular data, as well as the analytical platform Lens.
The objectives are to scrutinise data from subject cohorts to direct the development of biomarkers and subject stratification, formulate hypotheses for drug combinations, provide support in discovering new targets and offer insights into the healthcare experiences of patients.
Boehringer Ingelheim computational innovation head Jan Nygaard Jensen stated: “Leveraging real-world patient data is crucial for strengthening our data foundation and harnessing advanced AI methodologies, ultimately accelerating drug development.
“Integrating these comprehensive datasets with our internal data and techniques not only drives innovation but also enhances the precision and efficiency of pharmaceutical research, paving the way for groundbreaking medical advancements.”
Tempus is focused on progressing precision medicine by applying AI in healthcare.
Leveraging its multimodal data libraries and an operating system to make this data useful, the company offers precision medicine solutions to physicians for personalised care.
In April 2025, Boehringer, the University of Oxford and Cumulus Neuroscience initiated a study to monitor the activity of the brain in individuals with borderline personality disorder. This research is set to provide insights into the daily lives of those with psychiatric conditions.
In October 2024, Tempus AI and Avacta Therapeutics embarked on a strategic partnership to enhance oncology drug development.
"Boehringer partners Tempus AI to enhance cancer therapy pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.